Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data

Blinatumomab is a bispecific, CD19-directed, CD3 T-cell engaging, antitumor monoclonal antibody approved for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precurso...